-+ 0.00%
-+ 0.00%
-+ 0.00%

SYNDAX PHARMACEUTICALS - MAXPIRE PHASE 2 TRIAL OF AXATILIMAB IN IPF DOES NOT MEET PRIMARY ENDPOINT

Reuters·10/12/2026 20:01:00

Please log in to view news